We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
{{ subpage.title }}
US Vice President Kamala Harris
What We're Watching: Harris goes to Munich, French troops quit Mali, Japan's soft opening, Africa's mRNA mission
Harris goes back to the future in Bavaria. In recent years, the Munich Security Conference (MSC) – to say nothing of the broader transatlantic alliance – have suffered from a sense of unclear purpose. US President Donald Trump questioned NATO’s value, and French President Emmanuel Macron has called it “brain-dead.” Without the Cold War framework, many have asked whether NATO even has a purpose? But things couldn’t feel more different today, according to Eurasia Group President Ian Bremmer. “You’re talking about US leadership and an alliance that feels unprecedentedly threatened by the recent escalation in Ukraine from Russia,” said Bremmer from Munich on Thursday. And the face of that US leadership at Munich this year is US Vice President Kamala Harris, who will deliver an important address on Saturday. Harris, who was also tasked with handling the challenge of migration at the US-Mexico border last year, has struggled to shine in her historic role as the first female Veep. A powerful address at Munich, delivered in the thick of a major transatlantic security crisis, could be her moment in the sun.
French troops quit Mali. French and allied troops will leave Mali this year, ending a nearly decade-long deployment in the unstable West African nation aimed at quashing jihadist groups in the Sahel. Since an August 2020 coup, Mali has been run by a junta that has clashed with Paris, the former colonial power, over a range of security and political issues. Most recently, the junta postponed elections, which led to a spat and expulsion of the French ambassador. Many of the roughly 2,000 French troops in Mali will redeploy to neighboring Niger, French President Emmanuel Macron said Thursday. But keep an eye on Mali for what happens with two key players: jihadist groups and the Russian mercenaries whose presence there (and elsewhere in Africa) is irking Europe.
Japan eases “seclusion.” After two years of nearly total isolation, the Land of the Rising Sun will begin to ease pandemic-related travel restrictions next month. The world’s third-largest economy will gradually increase the number of daily arrivals by foreign business travelers and students, from 3,500 to 5,000, and reduce quarantine requirements. Although nearly 60% of Japanese polled say they prefer to keep the travel bans in place for now, Prime Minister Fumio Kishida has come under immense pressure from business groups that say restrictions are hobbling the economy. Some 150,000 foreign students have been locked out until now, waiting to put their visas to use. But don’t book that cherry blossom tour just yet: tourists are still not welcome.
Is Moderna thwarting Africa’s vaccine plans? Vaccine inequality has been a hallmark of the global pandemic. But there was some positive news last week when a South African biotech lab announced it had produced its first batch of mRNA jabs based on publicly available data from American vaccine maker Moderna. After much wrangling with European and American drug makers opposed to waiving intellectual property rights, the World Health Organization helped set up the African vaccine hub to address vaccine shortages in low-income countries. But now the Cape Town lab worries that its plans to start human trials by November will be scuttled after Moderna applied this week for vaccine patents in South Africa. The pharma giant says it won’t enforce any IP rules during the ongoing pandemic, but the African scientists clearly have their doubts. Moderna said last fall that it will spend $500 million to build a new facility in Africa that could produce up to 500 million vaccine doses per year.
What are the “known unknowns” about Moderna’s vaccine?
Moderna co-founder Noubar Afeyan concedes that there is plenty he still doesn't know about his company's COVID-19 vaccine, just as there's plenty he still doesn't know about the virus. But he is confident about one thing: "I view the vaccine as the best mask. It's a molecular mask, and once we have it onboard once, then presumably it will protect us." His conversation with Ian Bremmer was part of the latest episode of GZERO World.
Watch the GZERO World episode: A Shot in the Arm: Moderna's Co-Founder on the COVID-19 Vaccine
Moderna’s co-founder Noubar Afeyan on the growing pushback against a COVID-19 vaccine
"In any debate, if one side has to offer facts and the other side can offer doubts and they're considered of equal value, then the ones who offer doubts will always have an advantage." Moderna co-founder Noubar Afeyan isn't naïve about the pushback that his company's COVID-19 vaccine will receive when it hits the US market. Disinformation around vaccine safety and efficacy was rampant even before the pandemic began. His conversation with Ian Bremmer was part of the latest episode of GZERO World.
Watch the GZERO World episode: A Shot in the Arm: Moderna’s Co-Founder on the COVID-19 Vaccine